ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,049 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 251-275 of 1,000 matching filings.

Per page
25
Current page
11
6-K File 001-11960

FORM 6-K

Filing date
21 Oct 2024
Reporting date
21 Oct 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G

SC 13G

Filing date
11 Oct 2024
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET

Filing date
07 Oct 2024
Reporting date
07 Oct 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Oct 2024
Reporting date
01 Oct 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER

Filing date
26 Sep 2024
Reporting date
26 Sep 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA

Filing date
23 Sep 2024
Reporting date
23 Sep 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FINAL OS RESULTS REPORTED FOR TROPION - BREAST01

Filing date
23 Sep 2024
Reporting date
23 Sep 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US

Filing date
20 Sep 2024
Reporting date
20 Sep 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FASENRA EGPA US FDA APPROVAL

Filing date
18 Sep 2024
Reporting date
18 Sep 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Sep 2024
Reporting date
13 Sep 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 Sep 2024
Reporting date
02 Sep 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER

Filing date
16 Aug 2024
Reporting date
16 Aug 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Aug 2024
Reporting date
01 Aug 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING

Filing date
30 Jul 2024
Reporting date
30 Jul 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS

Filing date
29 Jul 2024
Reporting date
29 Jul 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER

Filing date
26 Jul 2024
Reporting date
26 Jul 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ACQUISITION OF AMOLYT PHARMA COMPLETED

Filing date
15 Jul 2024
Reporting date
15 Jul 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Jul 2024
Reporting date
01 Jul 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL

Filing date
01 Jul 2024
Reporting date
01 Jul 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
11-K File 001-11960

ANNUAL REPORT

Filing date
26 Jun 2024
Reporting date
31 Dec 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL

Filing date
25 Jun 2024
Reporting date
25 Jun 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER

Filing date
25 Jun 2024
Reporting date
25 Jun 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON CAPITELLO-290 PHASE III TRIAL

Filing date
18 Jun 2024
Reporting date
18 Jun 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER

Filing date
17 Jun 2024
Reporting date
17 Jun 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .